ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Generation Bio Company

Generation Bio Company (GBIO)

3.66
-0.11
(-2.92%)
Closed May 17 4:00PM
3.66
0.00
(0.00%)
After Hours: 5:59PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.66
Bid
3.26
Ask
3.66
Volume
91,125
3.59 Day's Range 3.9199
0.86 52 Week Range 6.98
Market Cap
Previous Close
3.77
Open
3.80
Last Trade
3
@
3.84
Last Trade Time
Financial Volume
$ 342,137
VWAP
3.7546
Average Volume (3m)
243,908
Shares Outstanding
66,477,111
Dividend Yield
-
PE Ratio
-1.93
Earnings Per Share (EPS)
-1.9
Revenue
5.9M
Net Profit
-126.61M

About Generation Bio Company

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases. Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Generation Bio Company is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GBIO. The last closing price for Generation Bio was $3.77. Over the last year, Generation Bio shares have traded in a share price range of $ 0.86 to $ 6.98.

Generation Bio currently has 66,477,111 shares outstanding. The market capitalization of Generation Bio is $243.97 million. Generation Bio has a price to earnings ratio (PE ratio) of -1.93.

GBIO Latest News

Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results

- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations...

Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting

Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid enzymatic synthesis continues to improve...

Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases...

Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases...

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3711.24620060793.294.342.832331893.41303985CS
40.9133.09090909092.754.342.72153513.11438524CS
121.5775.11961722492.094.652.03012439083.25453918CS
262.53223.893805311.134.651.13705002.19739721CS
52-0.91-19.91247264774.576.980.863641852.29817887CS
156-27.59-88.28831.2535.4050.863590487.51528946CS
260-18.49-83.476297968422.1555.720.8635972612.90294165CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DUOFangDD Network Group Ltd
$ 1.65
(313.74%)
104.67M
FLJFLJ Group Limited
$ 1.54
(220.90%)
57.28M
JFBRJeffs Brands Ltd
$ 0.6276
(102.45%)
37.97M
IPWiPower Inc
$ 2.89
(97.95%)
11.05M
CETXCemtrex Inc
$ 0.4851
(48.58%)
21.22M
BSFCBlue Star Foods Corporation
$ 0.0757
(-45.26%)
60.09M
SINTSiNtx Technologies Inc
$ 0.084602
(-39.57%)
156.33M
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
HSCSHeart Test Laboratories Inc
$ 7.00
(-38.11%)
348.9k
AMPGAmplitech Group Inc
$ 1.46
(-32.09%)
613.31k
CRKNCrown Electrokinetics Corporation
$ 0.171
(-28.75%)
1.73B
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
GWAVGreenwave Technology Solutions Inc
$ 0.1541
(4.05%)
1.16B
AKANAkanda Corporation
$ 0.1726
(30.26%)
566.3M
PEGYPineapple Energy Inc
$ 0.1053
(-28.85%)
219.2M

GBIO Discussion

View Posts
glenn1919 glenn1919 2 months ago
GBIO...................................https://stockcharts.com/h-sc/ui?s=GBIO&p=W&b=5&g=0&id=p86431144783
👍️0
willlbone willlbone 7 months ago
Welcome to Oct 2023. Buy the dip
👍️0
crudeoil24 crudeoil24 4 years ago
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering price of $19.00 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,578,947 additional shares of common stock at the initial public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.
Generation Bio has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading on Friday, June 12, 2020 under the ticker symbol “GBIO.” The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Generation Bio, are expected to be approximately $200 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on Tuesday, June 16, 2020, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 4 years ago
Generation Bio Co. is a genetic medicines company. The Company is developing a class of gene therapy utilizing its non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The Company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The Company is developing gene therapies to provide targeted delivery of genetic payloads that include multiple genes to a range of tissues of diseases. The Company is also engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The Company is a preclinical stage company and have not identified a product candidate.
👍️0